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CHAPTER 1 INTRODUCTION 
Background on Renal Failure   
Chronic kidney disease is a general term for a variety of different disorders 
affecting kidney structure and function. In the United States, the development of chronic 
kidney disease is associated with old age, diabetes, hypertension, obesity, and 
cardiovascular disease (Levey & Coresh, 2012). When unmanaged over long periods of 
time, these conditions cause damage to and destroy the nephrons, the functional units of 
the kidney. The diagnosis of chronic kidney disease is made through the presence of 
either kidney damage or decreased kidney function (as measured by glomerular filtration 
rate, GFR) below certain markers for a period of at least three months. When the kidney 
is functioning so weakly that dialysis or transplantation is necessary for the patient to 
survive (usually GFR < 15 mL/m2), the condition is labeled as “kidney failure,” also 
known as “end stage renal disease” (ESRD) or “stage 5 chronic kidney disease.” 
Prevalence is approximately 1,800 cases per million across the total population of the 
United States, and most patients survive only 3-5 years.  
For the majority of patients, ESRD is the end result of a progressive deterioration 
in kidney function over a period of months or years. Although it is possible to reverse the 
course of disease progression through treatment, that outcome is uncommon. The major 
focus of treatment is to slow the progression of the disease and manage complications. 
Most patients with ESRD undergo hemodialysis (as opposed to peritoneal dialysis) in 
which a machine serves about 15% of the function of healthy kidneys, but this process 
requires a time commitment of 3 days per week for 3-4 hours each time. Additionally, 
most patients with ESRD have other complex medical complications such as 
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cardiovascular disease and diabetes, which require a strict medication regimen to be 
controlled. This places the responsibility of strict medication adherence in the hands of 
the patients, in addition to their other burdensome requirements of undergoing dialysis, 
and consuming reduced amounts of fluids and sodium. Finally, renal transplantation 
offers better long-term outcomes than dialysis, but the supply of available kidneys is 
limited. 
Early Readmissions 
Readmissions within 30 days after discharge from the hospital are an increasingly 
important metric for evaluating the effectiveness of medical treatment. Hospital 
admissions are the single most expensive episodes in healthcare, and early readmission 
has been targeted as indicating a likely failure of appropriate care and/or discharge 
preparation. In fact, the Affordable Care Act has instituted a policy of fining hospitals for 
high 30-day readmission rates as means of incentivizing those hospitals to provide quality 
care. Yet, the ESRD patient population has the highest rate of 30-day readmissions of all 
patients in the Medicare/Medicaid population, averaging over 30% across all hospitals 
(Medicare Payment Advisory Commission, 2007). Therefore, interventions that reduce 
these early readmission rates could make an enormous difference in both improving care 
for patients with ESRD while also saving money for hospitals. Yet, few interventions 
have ever been developed or empirically tested via a randomized controlled trial (RCT) 
to modify this outcome variable. An added benefit of reducing hospital admissions is that 
it keeps patients out of danger from medical errors, which have been estimated to result 
in over 210,000 deaths per year in the United States (James, 2013). The following 
sections present five major behavioral risk factors (shown in Figure 1) for early 
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readmissions in patients with ESRD, although as I discuss below, only social support 
may be amenable to adaptive change with a brief intervention. 
 
 
Figure 1. Proposed Model 
Risk Factors 
Cognitive Impairment 
Cognitive impairment, an umbrella term that includes both chronic and acute 
deficits in cognitive functioning, is increasingly recognized as a primary psychosocial 
risk factor for excessive healthcare utilization and hospital admissions. In general, the 
most common cause of cognitive impairment is the normal aging process. Patients with 
ESRD are particularly at risk due to their high comorbidity with medical conditions that 
affect the central nervous system, such as hypertension, diabetes, smoking, and 
Early	Readmission	Poor	Adherence	
Cognitive	Impairment	Low	Health	Literacy	Substance	Abuse	
Depression	
Low	Social	Support	
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atherosclerosis (Ketterer, Soman, & Mossallam, 2014). Furthermore, patients with ESRD 
are also at risk for delirium resulting from various causes, such as encephalopathy due to 
the failing kidney (increased uremia, hyperkalemia, hyperphosphatemia, and acidosis) 
and side effects from medications. Delirium, which is characterized by confusion, 
disorientation, and attention problems that fluctuate over time, has been shown to have 
particularly negative consequences for both patients and support members (O'Malley, 
Leonard, Meagher, & O'Keeffe, 2008). Cognitive impairment has been found to be 
related to poor self-care adherence (Cameron et al., 2010) and to prospectively predict 
readmission and mortality (Dodson, Truong, Towle, Kerins, & Chaudhry, 2013; Watson 
et al., 2011). Cognitive impairment also may be the principle factor for early readmission 
in at least some populations, such as those with congestive heart failure (Ketterer, Draus, 
McCord, Mossallam, & Hudson, 2014). Preliminary analyses have replicated these 
findings in the very hospital where I conducted this study. A prospective study assessed 
patients with ESRD for a variety of different risk factors when they were initially 
admitted to the hospital, and found that cognitive impairment, substance abuse, and low 
health literacy at baseline predicted 30-day readmissions (Ketterer, Soman, et al., 2014). 
Additionally, an unpublished retrospective review of medical records of patients with 
ESRD that I conducted showed that the presence of one or more positives on a "cognitive 
composite" index (history of delirium, positive head CT or MRI, history of seizures, 
history of hypoxia) was significantly related to the presence of a 30-day readmission 
within the past year (Jasinski, Lumley, Soman, Yee, & Ketterer, in press). Unfortunately, 
cognitive impairment is rarely identified in healthcare settings, and usually remains 
unattended to in this population (Tamura & Yaffe, 2011). Therefore, simply raising 
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awareness about cognitive impairment in patients with ESRD might help their physicians, 
other medical staff, and support people plan for appropriate home care after discharge. 
Depression 
Patients with ESRD face unique psychological stressors due to their extreme 
dependence on technology for survival as well as the time-consuming demands on their 
health behaviors (Christensen & Ehlers, 2002). Living with ESRD entails a variety of 
chronic, recurrent stressors, significant change in lifestyle, disruption of familial roles and 
social identity, and threatened personal control, mainly due to the requirements for 
dialysis. Psychological distress and disorder represent a significant detriment to ESRD 
patient quality of life. Estimates of the prevalence of depression in this population are 
that 20-25% of ESRD patients meet diagnostic criteria for major depression (Kimmel, 
Cukor, Cohen, & Peterson, 2007). The loss of control that comes with ESRD has been 
identified as an important contributing factor to this depression. Illness intrusiveness, 
which is very high due to the requirements of hemodialysis, has also been shown to be a 
contributor to depression (Christensen & Ehlers, 2002). Additionally, depression may be 
under recognized and under treated in this population, and even when intervention 
attempts are made, treatment has often been unsuccessful (Fallon, 2011).  
Substance Abuse 
Cocaine and other substances have been identified as causes and exacerbating 
factors of renal failure (Norris et al., 2001). Accordingly, substance abuse is very 
prevalent in patients with ESRD, in spite of the fact that it accelerates the deterioration of 
their health (Kimmel, Thamer, Richard, & Ray, 1998). In general, substance abuse has 
been linked with greater health care utilization, especially in populations with low socio-
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economic status (Kushel, Vittinghoff, & Haas, 2001). In a study conducted at Henry Ford 
Hospital, where I conducted this dissertation, substance abuse prospectively predicted 
early readmissions in patients with chronic kidney disease. Finally, although the impact 
of substance abuse on interventions with inpatients is largely unknown, it could be an 
important moderating variable. For example, substance abuse could potentially be a 
barrier to the success of the intervention. 
Health Literacy 
Another psychosocial factor attracting much attention is “health literacy,” defined 
as the ability of patients to understand the language used to educate them regarding their 
medical conditions as well as the medical treatments used to manage their health (Kindig, 
Panzer, & Nielsen-Bohlman, 2004). Low health literacy has been associated with various 
adverse outcomes including an increase in hospital admission/readmission rates (Baker, 
Parker, Williams, & Clark, 1998; Mitchell, Sadikova, Jack, & Paasche-Orlow, 2012). In 
the case of patients with ESRD, increased mortality has also been found to be associated 
with low health literacy (Cavanaugh et al., 2010). However, the mechanism by which 
health literacy impacts outcomes is unclear, and the possibility of a third factor such as 
socioeconomic status that confounds or mediates any observed association must be 
considered and controlled or eliminated. For example, research has shown that the 
improvements assumed to occur with greater health literacy—better disease knowledge, 
healthier behaviors, more use of preventive care, and compliance—could not account for 
a relationship between health literacy and use of hospital services (Cho, Lee, Arozullah, 
& Crittenden, 2008). Most important of all, there have been no randomized controlled 
trials providing evidence that health literacy is a causal variable (Ketterer, Mahr, & 
	 7	
	
Goldberg, 2000). In summary, education-focused and behaviorally-based interventions 
focus on helping patients by improving their health literacy, which is certainly an 
important variable. Some of these interventions have even included family and friends to 
a certain extent.  
Social Support 
Although there are many variables that are risk factors for poor outcomes in 
patients with ESRD, social support serves as a protective factor. Additionally, whereas 
there is little or no evidence that we can use brief bedside interventions to attenuate the 
above risk factors and improve outcomes in patients with ESRD, there is evidence that 
psychosocial interventions involving family members can reduce patient and caregiver 
burden, and improve mood in these patients with various chronic illnesses (Martire, 
Lustig, Schulz, Miller, & Helgeson, 2004). In general, health literacy and individual 
differences in health behavior are often implicated as potential mediators of the 
association between social support and physical health (S. E. Cohen & Syme, 1985). 
Therefore, an increase in social support could help compensate for the presence of these 
risk factors. Also, a supportive family environment has been identified as a particularly 
important protective factor for chronically ill individuals in terms of self-management of 
their health behaviors such as diet (Gallant, 2003). As is the case with other clinical 
populations, various indices of the quantity and perceived quality of social support have 
been associated with more favorable psychological adjustment and reduced risk of 
mortality among patients with chronic kidney disease (Christensen, Wiebe, Smith, & 
Turner, 1994; S. D. Cohen et al., 2007). Perceived social support is also associated with 
less depressive and suicidal thoughts among patients with ESRD (Soykan, Arapaslan, & 
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Kumbasar, 2003). 
Potential Mediator: Medication and Dialysis Adherence 
Patients with ESRD have a reputation for being “difficult” to work with, because 
their medical cases are usually complex, and adherence is commonly lower than among 
patients with other diseases (Christensen & Ehlers, 2002). One explanation for low 
adherence involves the high burden experienced by patients with ESRD. For example, 
patients on hemodialysis are required to commit to three dialysis sessions per week, 
which take a few hours each time. In addition, patients are prescribed dietary restrictions 
that significantly limit their food options. Therefore, it is unsurprising that many patients 
say that they feel “over-doctored” and overwhelmed by the amount of self-care that is 
necessary for them to survive (Levy, Cohen, & Tessier, 2006). Studies examining the 
prevalence of nonadherence among renal dialysis patients have typically observed that 
between 30% and 60% of patients do not adhere to diet, fluid-intake, and medication 
regimens (Bame, Petersen, & Wray, 1993). These studies have relied almost entirely on 
cross-sectional, self-report assessment of patient characteristics and adherence outcomes. 
Adherence to health behaviors such as taking medications as prescribed and 
attending dialysis sessions has been proposed as the primary mechanism by which the 
various risk factors described above lead to early readmissions, and represents a mediator 
by which risk factors translate into poor health outcomes. Patients with ESRD have a 
unique set of clinical, socio-demographic, and psychosocial factors that have been 
examined as potential correlates or determinants of adherence behavior, including 
cognitive impairment, family support, depression, health beliefs, and health literacy 
(Cameron et al., 2010; Karamanidou, Clatworthy, Weinman, & Horne, 2008). Simply, 
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patients who are too forgetful or confused to take their medications regularly experience 
negative health effects (including mortality) as a result, and, therefore, require 
hospitalization in order to recover (Kimmel, Peterson, et al., 1998; Kimmel et al., 2000; 
Leggat et al., 1998). For example, cognitive impairment, depression, substance abuse, 
and younger age have all been linked to worse hemodialysis adherence (Mellon, Regan, 
& Curtis, 2013).  
Social Support and Adherence 
Limited research is available regarding the relationship between social support 
and adherence among patients with ESRD. For example, there is a large body of research 
in other populations that suggests that many different aspects of social support 
(emotional, practical, etc.) are important correlates of regimen adherence (DiMatteo, 
2004). Christensen et al. (1992) examined the effects of family social support and illness-
related stress on hemodialysis patient adherence. Patients who reported a more supportive 
family environment, characterized by greater cohesion and expressiveness among family 
members and less intrafamilial conflict, exhibited significantly more favorable adherence 
to fluid-intake restrictions than did patients reporting less family support. Likewise, being 
married has been linked to increased adherence to hemodialysis (Alkatheri et al., 2014). 
A major limitation of the research is that family and social support interventions 
have not been tested within patients with ESRD to determine how they might impact 
medication adherence or the specific health outcome of early readmissions after hospital 
discharge. On the other hand, this lack of data presents an opportunity to test the ability 
of health care professionals to mobilize social support, which may be more amenable to 
change than the other risk factors of early readmission, such as cognitive impairment, 
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health literacy, depression, and substance abuse. Additionally, across the literature, the 
impact of social support has been assessed using a variety of different measures, which 
means that there is robust evidence that shows social support to be a protective factor in 
patients with ESRD. But, the downside is that social support is a broadly defined 
construct, so it is difficult to determine which specific factors might carry the most 
impact in a potential intervention. 
Interventions for adherence 
Given the prevalence of ESRD and clinical importance of adherence among 
patients diagnosed with this condition, the design and evaluation of interventions to 
improve adherence is critically important. The ESRD population has been identified as 
ripe for specific interventions designed to mobilize social support (Chisholm‐Burns, 
Spivey, & Wilks, 2010; Cukor, Rosenthal, Jindal, Brown, & Kimmel, 2009). However, 
most interventions in this population have not attempted to utilize social support, and no 
interventions have been tested for their ability to reduce early readmissions in patients 
with ESRD. Therefore, in this section I will review interventions that have aimed to 
improve my primary hypothesized mediator variables, medication and dialysis adherence. 
Most ESRD adherence intervention studies (at least 10 in total) have used 
behaviorally-oriented techniques. There is evidence to suggest that a range of behavioral 
strategies (e.g., self-monitoring, behavioral contracting, and positive reinforcement) are 
associated with small to medium effect size improvements in adherence among 
hemodialysis patients (Matteson & Russell, 2010). However, many of these studies are 
limited to single-subject or very small sample designs, and conducted over multiple 
sessions with outpatients. For example, a pre-post design study showed that a 3-month 
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motivational interviewing intervention improved dialysis attendance as well as 
biomarkers of kidney health at follow-up (Russell et al., 2010). Also, Binik et al. (1993) 
reported that a brief, enhanced-education intervention focusing on increasing patient 
knowledge about the basic pathophysiology of kidney disease, and options for treatment 
strategies led to a delay in the need to initiate renal dialysis compared with a standard-
education control group. Cukor et al. (2013) conducted a large cognitive behavioral 
therapy (CBT) intervention that occurred while patients were seated at their hemodialysis 
appointments, and found that the CBT group demonstrated significantly higher adherence 
to fluid intake restrictions (among other psychosocial improvements), but no 
improvement with adherence to prescription medications, when compared to a wait-list 
control group. These interventions, although somewhat encouraging, would not be as 
feasible with inpatients, particularly those with cognitive impairment, who, in 
comparison, are much sicker than those in outpatient dialysis units. 
Putting it all together: Considerations for intervention  
In terms of the focus of the intervention, there are several risk factors that have 
been previously targeted for intervention in this population, including depression and 
substance abuse. However, these variables have already been investigated, and usually 
take many recurring sessions of treatment before any improvement is noticeable. 
Therefore, this study, although not ignoring these variables, placed an emphasis on 
domains that have not yet been tested, such as compensating for cognitive impairment. A 
key aspect of this study is that we targeted patients who had already demonstrated the 
lack of capacity for proper adherence, and are most at risk for poor adherence and 
readmissions, in order to work with those who need the most help and use the most 
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resources. These patients likely would not respond very well to the CBT interventions 
that have already been tested. Of the five risk factors for poor adherence and early 
readmissions mentioned above, social support is the one with the most potential to be 
modified by a brief family consultation. Thus, mobilizing family support to help patients 
adhere to their medication schedule is something that can potentially be achieved in one 
brief psychoeducation session. In addition, family involvement could help benefit 
patients with low health literacy as well. 
There are several other considerations for the process of the intervention. First, 
the consultation-liaison literature has demonstrated that bedside psychiatric consultations 
can maximize efficiency as well as reducing patient burden (Griffith & Gaby, 2005). 
Accordingly, we kept the intervention brief to minimize the burden on patients and their 
support people, as well as reducing the potential cost of this intervention in a real-world 
setting. Importantly, pragmatic research methods like this would allow this study to 
achieve the goal of being more on the effectiveness side of the spectrum as opposed to 
efficacy. Second, health literacy issues will need to be considered as a common concern 
in this population. Interventions to improve health literacy have included advocating the 
importance of use language that is easy to understand, promote empowerment in patients, 
and mobilize social support (Gazmararian, Jacobson, Pan, Schmotzer, & Kripalani, 
2010). However, the goal of the intervention is to compensate for low health literacy, 
rather than to try to change health literacy. Therefore, as part of this intervention, it will 
be important to use words that patients can understand and do not provoke defensive 
responses, such as discussing “forgetfulness” instead of “cognitive impairment” or 
“dementia.”  We also utilized motivational interviewing techniques as necessary when 
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patients were resistant or skeptical of the intervention (Levy et al., 2006; Miller & 
Rollnick, 2012). Furthermore, although attending to medications and dialysis will be the 
main focus of the intervention, it would be efficient to mention the importance of 
managing any evident depression symptoms and abstaining from alcohol and other 
substances.  
There is some debate regarding the optimal way to quantify the outcomes of this 
study. We used 30-day inpatient readmissions as a dichotomous variable as our main 
outcome because that is the statistic currently attracting attention due to its use by CMS 
to determine fines for high readmission rates. This metric is also easy to understand and 
face valid for explaining to patients and other people who are not versed in the 
complexities of hospital procedures. However, return visits for observation or to the 
emergency department are also clinically relevant and important metrics for patient 
health and quality of life as well as evaluating hospital performance and funding. 
Therefore, we created a second variable to encompass whether or not a patient had any 
type of return visit. Finally, readmission status at three months was also assessed as a 
secondary outcome variable. 
Summary and Goals of Study 
A variety of risk factors cause poor medication and dialysis adherence in patients 
with ESRD, but increased family support may be able to counteract these limitations and 
improve adherence. The main goal of this study was to use a randomized clinical trial to 
test the efficacy / effectiveness of a brief family meeting consultation aimed at improving 
the health behaviors of patients with ESRD to prevent early readmissions to the hospital. 
We will also analyze observation status and emergency department visits as outcomes 
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because although they are not yet being targeted by the Affordable Care Act, they 
represent clinically relevant outcomes. As secondary goals, we investigated the mediators 
of this process by monitoring changes in social support, medication and dialysis 
adherence, and mood and their relation to the outcome variables. Baseline cognitive 
impairment and history of substance abuse were examined as moderators.  
 Finally, I sought to replicate our preliminary study linking cognitive impairment 
with 30-day readmissions because these findings are relatively novel in the literature and 
may have important implications for potential mechanisms of this intervention. This was 
done by examining if baseline cognitive impairment indicators from the chart review 
predicted readmissions for the sample as a whole, ignoring experimental condition 
assignment. 
Hypotheses I	hypothesized	that:		
 (1) The intervention group would have significantly fewer 30-day (and 3 month) 
readmissions and hospital visits than the medical treatment-as-usual control group. 
(2) Social support and adherence would increase more in the intervention group than the 
control group, and would mediate the relationship between condition assignment and 
outcomes.  
(3) Baseline cognitive impairment and history of substance abuse were run as exploratory 
moderator analyses, so no hypotheses were made.  
(4) Measures of cognitive impairment from the chart review and baseline assessment 
would positively predict 30-day readmissions. 
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CHAPTER 2 METHODS 
Participants 
Participants were 120 adults who had end stage renal disease and were 
hospitalized at Henry Ford Hospital in Detroit, Michigan. Inclusion criteria were a 
current admission to the Nephrology unit and willingness to contact a family member or 
friend who was expected to be available and responsive to the consultant, if the patient 
was randomized into the experimental condition. To maximize generalizability of this 
sample to the larger population of patients with ESRD, there were few exclusion criteria: 
delirium, unavailability/discharge before recruitment and informed consent, and inability 
to speak English. Patients were paid $40 for their participation in the study ($20 at 
baseline and $20 at follow up). 
Procedure 
Risk Factor Screening Chart Review 
A chart review was used as a screening measure to identify the patients admitted 
to the Nephrology unit who are most at risk for readmission. A pilot study (Jasinski et al., 
in press) found that age and cognitive impairment variables (such as history of delirium 
and positive brain imaging results) can be used as screening variables to identify which 
patients in the nephrology unit are at higher risk for being readmitted to the hospital 
within 30 days. The experimenter tried to recruit all patients with ESRD, but, given time 
constraints, when multiple patients were available for recruitment simultaneously, 
priority was given to patients who screened positive for one or more risk factors for early 
readmission.  
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Recruitment and Randomization  
 This trial was registered at clinicaltrials.gov (NCT02504021) prior to recruitment, 
which ran from August 2015 to April 2016, with outcome assessment completed in May 
2016. The randomization scheme was created before recruitment began by an 
independent research assistant. Randomization was conducted using randomization.com; 
it was stratified by patient gender (male or female), conducted in randomized blocks of 6 
or 8, and the assignments were placed in sealed envelopes. Figure 1 presents the flow of 
patients through the trial. All recruitment and intervention procedures were conducted by 
a trained, male, clinical psychology doctoral student, who was supervised by a doctoral 
psychologist with extensive experience in health psychology interventions. Patients were 
approached at bedside, and those who met study criteria provided written, informed 
consent to the IRB-approved protocol. Patients then completed an initial assessment 
using several questionnaires, some of which informed the subsequent family consultation 
(see below). Questionnaire items were read aloud by the researcher to assure the patient’s 
understanding, given concerns about literacy in this population. Following the 
assessment, the researcher unsealed the envelope to determine the assigned condition; 
patients and the researcher were blind to condition assignment prior to this.  
 As part of the screening process at the initial meeting, we carefully discussed with 
the patients whether or not they had a reliable family member or friend (ideally living in 
the same household) who might be willing to come meet with us at the hospital. Those 
participants who potentially met study criteria and remained interested were invited to 
review the study procedures, provide written, informed consent, and complete baseline 
questionnaires. Then, they were randomized into the experimental or control condition. 
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Finally, the researcher verbally assessed stress level and stage of change regarding 
openness to having someone help with their medications (Miller & Rollnick, 2012). This 
information was used in planning for the family consult, which was designed to remain 
flexible as would be consistent with a motivational interviewing approach. 
 For patients randomized into the consultation condition, the researcher spoke with 
them about selecting a family member or friend to come to meet them in the hospital and 
agreeing to participate in the study. We also scheduled a time for the appointment and 
confirmed with the support people that they could attend. However, in-person family 
meetings were often not feasible, so to maximize participation and feasibility, some 
family consultations occurred by telephone. In such cases the consultation was conducted 
with the family member over the phone, and patients were briefed about the content of 
the discussion.  Then, the family meeting was conducted as soon as possible, ideally 
before the patient was discharged. Support people were provided with information sheets 
when meetings were in-person, and provided verbal consent for consults that were done 
over the phone. Family meetings were conducted in-person when the family was already 
present at the hospital. Method of contact was recorded for analysis as a potential 
moderator. 
At follow-up, a chart review was conducted by a member of the research team 
one month after the discharge of each participant to determine if he or she was readmitted 
to the hospital within that time frame (which represents the window where hospitals are 
financially penalized).  Other variables such as observation status admissions and 
emergency department visits were also recorded. All codes for readmissions were 
independently confirmed by a senior hospital psychologist who was blinded to patient 
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randomization. We reviewed the charts again at three months to assess longer-term 
readmission status as a measure of health. There was little data available about 
readmissions to hospitals outside of the Henry Ford, so it was not included. Patients in 
both the consultation and control conditions were called to administer the follow-up 
measures after 1 month, and if patients could not be reached via phone after three 
attempts, were mailed with return envelopes. 
Family Consultation Condition 
 The family consultation consisted of one relatively brief session. To maintain trial 
integrity and avoiding confounding by the medical team, the doctoral student / family 
consultant worked independently from the rest of the health care team on the unit, leaving 
them essentially blind to patient consultation condition.  
 The consultation had several components. The consultant: 
1) introduced himself and informed the patient and family member that the health care 
team is working to improve post-discharge care by communicating better with the 
patient’s support people; 
2) built rapport by providing empathy regarding the burden of managing ESRD; 
3) reviewed patient and family understanding of events that caused the hospital 
admission; 
4) educated patient and family about of the level of cognitive impairment that the patient 
was experiencing by discussing the results of the initial cognitive assessment; 
5) discussed ways for the support person to assist the patient with his or her medication 
adherence, even when the patient displayed no overt signs of cognitive impairment; 
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6) tailored the consultation to each patient by including other risk factor data from the 
initial assessment (i.e., health literacy, social support, and adherence) as indicated; 
and  
7) used motivational interviewing techniques, as indicated, such as asking permission to 
make recommendations, and reflecting ambivalence over treatment adherence.  
The detailed protocol is included in Appendix A. 
Control Condition 
After the initial patient assessment, control participants engaged only in their 
medical treatment as usual (TAU). No family consultation was conducted.  
Screening and Predictor Measures (Baseline only): 
Demographic and Medical Status Variables 
A researcher conducted the review of the following variables: age, gender, race, 
history of substance abuse, history of delirium, history of seizures, history of hypoxia, 
history of psychiatric history, presence of psychiatric medications, number of past year 
hospital readmissions, length of time on dialysis, comorbid health conditions, serum 
creatinine, BUN level, and phosphorous.	
Cognitive impairment 
Cognitive impairment and education was assessed with The Montreal Cognitive 
Assessment (MoCA; (Nasreddine et al., 2005)), which is a brief (~10 minute), easily 
administered and scored screening instrument to detect cognitive impairment among 
patients in medical settings. It was designed to provide physicians a method of 
assessment for dementia that can be done quickly and requires minimal training to 
administer and score. The measure assesses: a) executive function (after being given a 
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full sheet of paper with a large circle drawn on it, patients are instructed, “Draw me a 
clock, put all the numbers on it and make it say 10:15”); b) naming (“What are these 
three animals?”); c) immediate memory (“Repeat these three numbers: 2, 1, 8, 5, 4”); d) 
language (world fluency and sentence repeat); e) abstraction (similes); f) short-term 
memory (after a 5 minute delay during which the patient was distracted: “What were 
those five words I read to you earlier you?”); and g) orientation (“Name the current date 
& building we are in.”). Finally, 1 point is added to the score of patients who have no 
education beyond a high school level. 
 Health Literacy 
The Rapid Estimate of Health Literacy in Medicine (REALM) (Davis et al., 1993) 
is a brief screening instrument designed for use in medical settings to assess patients’ 
reading level. The instrument consists of having patients read two lists of 8 and 7 words 
aloud and usually takes less than 2 minutes. Patients are scored one point for each word 
that they pronounce correctly. Scores are interpreted in terms of grade equivalent reading 
level, with a perfect score corresponding to an above 9th grade level reading capability. 
Outcome Measures: 
Outcome Measure: Early Readmissions 
 The outcomes for this trial were obtained from the electronic medical record of 
each patient. The primary outcome variable for this study was early (30-Day) hospital 
readmissions. We operationalized this variable in two ways. First, we calculated the 
percentage of study patients who had another inpatient readmission within 30 days of 
discharge. This metric is easy to understand and directly relates to the financial penalties 
levied by the Affordable Care Act, but may be lacking in nuance and fail to capture the 
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range of negative events. Thus, we also calculated the percentage of patients who had any 
unplanned return visit to the hospital (inpatient readmissions, observation unit visits, and 
emergency department visits) within 30 days of discharge. We believe that the 
observation and emergency department visits represent clinically relevant outcomes and 
therefore should also be studied in an effort to prevent them. All outcome data were 
initially retrieved by the consultant, and then independently retrieved by a senior staff 
member who was blinded to experimental condition. Complete agreement between the 
two coders was over 98%; the few differences were resolved by discussion and 
consensus. 
Social Support 
At both baseline and follow-up, perceived social support was assessed using items 
from the Modified Scale of Social Support-5 (MSSS), which is an abbreviated version of 
the full-length MSSS (Sherbourne & Stewart, 1991). This self-report questionnaire takes 
about 2-3 minutes to complete and has a Cronbach’s alpha of .87 (Sherbourne & Stewart, 
1991). Items are rated on a scale of 1 (None of the time) to 5 (All of the time). Higher 
scores indicate greater perceived social support. Item domains include 
emotional/informational support, tangible support, affectionate support, and positive 
social interaction. This questionnaire has been used in important studies linking social 
support with adherence in patients with ESRD (Chisholm‐Burns et al., 2010). Internal 
consistency in this sample was α = .77 at baseline and α = .73 at 1-month follow up. 
 Medication Adherence 
At both baseline and follow-up, adherence to medication was assessed using a 
modified version of the Immunosuppressant Therapy Adherence Scale (ITAS) 
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(Chisholm, Lance, Williamson, & Mulloy, 2005). The only change to this scale was to 
change the language from immunosuppressant medication to include all medications. 
Several studies have provided evidence for the validity of this measure to assess 
adherence in organ transplant populations and has specifically been used in patients with 
ESRD. The 4 items refer to behaviors over the past month: “How often did you forget to 
take your medications?; How often were you careless about taking your medications?; 
How often did you stop taking your medications because you felt worse?; How often did 
you miss taking your medication for any reason?” The four response options for each 
item are 0% of the time, 1-20%, 21-50%, and over 50% of the time. Internal consistency 
was found to be Cronbach’s α = .81 during initial development. (Chisholm et al., 2005). 
A fifth item, “How often did you miss your planned dialysis sessions?,” was also added 
for this study. Including this item, internal consistency was α = .78 in this sample at 
baseline, and α = .74 at 1-month follow up. 
Depression 
At both baseline and follow-up, depression was assessed using the Patient Health 
Questionnaire-8 (PHQ-8) (Kroenke, Spitzer, & Williams, 2001). This measure is one of 
the most widely used assessment tools in healthcare settings. It consists of 8 items based 
on the diagnostic criteria for major depressive disorder, with response options ranging 
from 0 (Not at all) to 4 (Almost every day) asking about the patients’ experiences over 
the past two weeks. Higher scores indicate greater depression. Cronbach’s alpha for this 
measure was .89 during initial validation, and in this sample was .81 at baseline and .82 
at 1-month follow up. 
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Anxiety 
At both baseline and follow up, anxiety was assessed using the Generalized 
Anxiety Disorder 7-Item Scale (GAD-7) (Spitzer, Kroenke, Williams, & Löwe, 2006). 
The measure is one of the most widely used assessment tools for anxiety. Items are rated 
from 0 (Not at all) to 3 (Nearly every day); higher scores indicate greater anxiety. 
Cronbach’s alpha for this measure during initial validation was .89, and in this sample 
was .84 at baseline and .91 at 1-month follow up. 
Researcher Ratings Post-Consultation 
 A rating scale was developed for this project to characterize and describe the 
family meetings. The first section of the scale contained 9 items ranging from 0 (not at 
all) to 4 (a lot) that allowed the consultant to subjectively rate the interactions with the 
family and perceived success of the meeting. Example items referring to the perceived 
reactions of the support people were “developed greater awareness of barriers to 
adherence” and “seemed to appreciate the consult.”  
Statistical Analysis 
The trial was powered to detect a difference between consultation and control 
conditions of 20%, which we estimated to be a clinically meaningful effect. To obtain 
power of .80 using a chi-square test and 1-tailed (directional) alpha of .05 indicated that 
at least 55 patients per condition were needed (that is, at least 110 patients). Recruitment 
also targeted and achieved equal numbers of men and women. Initial analyses examined 
the success of randomization by comparing background demographic, medical, and 
psychosocial measures between the consultation and TAU control conditions. 
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Primary, intent-to-treat analyses of the effects of the consultation versus control 
condition on the presence / absence of readmission were conducted with 2x2 chi square 
tests. Treatment effects on continuous variables (i.e., social support, anxiety, depression, 
adherence) variables were tested using repeated measures ANOVA comparing baseline to 
1-month follow up scores. As detailed below, three patients never received their 
randomly assigned consultation, so in addition to intent-to-treat analyses of all 
randomized patients, we also ran “per protocol” analyses, comparing those patients who 
received the consultation to all controls.  
For statistical tests with hypothesized direction (consultation condition vs. TAU 
in readmission and return hospital visits), we used 1-tailed tests with an alpha of .05; all 
other tests were 2-tailed with alpha at .05. 
For effect sizes, I calculated number needed to treat (NNT); that is, the number of 
patients who would need the consultation to prevent a negative outcome (an early 
readmission or unplanned hospital visit), compared to TAU. I also calculated effect sizes 
for all 1-month self-report outcomes. The between-condition effect size for secondary 
outcome variables were calculated at follow-up using the following equation: [(Family 
Consultation follow-up M – baseline M) – (TAU follow-up M – baseline M)] / SD of the 
pooled baseline scores. Effect sizes of 0.2 SD, 0.5 SD, and 0.8 SD are considered small, 
medium, and large, respectively.  
A few analyses were run in an exploratory fashion: regressions to test cognitive 
impairment as a moderator, and the predictive value of therapist post-session ratings. 
Also I ran t-tests and Chi-squares to examine if any of the baseline variables predicted 
30-day readmissions. Finally, I ran some supplementary medical cost offset analyses to 
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estimate the amount of money potentially saved by this intervention, as a function of the 
difference in days of inpatient stays resulting from readmissions between the two groups. 
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CHAPTER 3 RESULTS 
Sample Descriptives 
As shown in Figure 1, we screened 171 patients and randomized 120 of them. I 
approached 51 other patients about participation, and 15 did not meet study criteria, 31 
declined to participate, and 5 were excluded for miscellaneous reasons. As shown in 
Table 1, the randomized sample was half male and half female, had a mean age of 57.5 
years (SD = 14.4; range = 24-88), was predominantly African American (85.8%), and 
less than half (42.5%) had education beyond high school. In addition to their ESRD 
diagnosis, most patients had many medical comorbidities, some of which are shown in 
Table 1. The two conditions were compared on these background variables to determine 
the success of randomization; none of the variables differed significantly between 
conditions. Note: Based on statistics available from this hospital, the 30-day readmission 
rate for patients with ESRD is around 25%, which is slightly below the national average. 
The 30-day readmission rate in this sample was 32% in the TAU control group, therefore 
it is possible that this sample was slightly more at-risk than the usual hospital population. 
 The consultation was conducted as planned for 57 of the 60 patients randomized 
to the family consultation condition. Family consultations did not occur for 3 patients, for 
whom the interviewer was unable to reach any support person, even after three attempted 
telephone calls. The 57 consultations were relatively brief, averaging about 8 min (SD = 
5.0 min, range: 2 to 30 min); 23 consultations (40%) were conducted with the family at 
bedside, and the rest were conducted over the telephone. Consultations involved a variety 
of different support people: 17 (30%) spouses, 12 (21%) children, 10 (16%) parents, 6 
(11%) siblings, 6 (11%) multiple people, 6 (11%) non-relatives. 
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Figure 2. CONSORT Flowchart 
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Randomization Check 
Table 1 presents the sample data on 30 baseline variables that were compared 
across treatment groups to determine the success of randomization. At a confidence level 
of p < .05, there were no significant differences between the two groups, and therefore we 
deemed the randomization to be successful. 
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Table 1. Characteristics of the full sample and family consultation and 
control conditions separately 
 Variable Total 
N = 120 
Consultation 
n = 60 (50%) 
Control 
n = 60 (50%) 
t or 
χ2 
Demographics     
   Age (M, SD) 57.5 (14.4) 58.0 (13.9) 56.97 (15.1) -1.03  
   Gender (Male) 60 (50.0%) 30 (50.0%) 30 (50.0%) 0.00 
   Gender (Female) 60 (50.0%) 30 (50.0%) 30 (50.0%) 0.00 
   Race (Black) 103 (85.8%) 51 (83.0%) 52 (86.7%) 0.08 
   Race (White) 17 (14.2%) 9 (15.0%) 8 (13.3%) 
   Grade > 12th  51 (42.5%) 24 (40.0%) 27 (45.0%) 0.31 
Medical risk factors     
   Congestive heart failure 58 (48.3%) 28 (46.7%) 30 (50.0%) 0.13 
   Smoking 71 (59.2%) 35 (58.4%) 36 (60.0%) 0.34 
   Diabetes 74 (61.7%) 42 (70.0%) 32 (53.3%) 3.53 
   Hypertension 118 (98.3%) 59 (99.2%) 59 (99.2%) 0.00 
   COPD 22 (18.3%) 10 (16.7%) 12 (20.0%) 0.22 
   Blood Urea Nitrogen (M, SD) 40.72 (22.65) 38.42 (18.67) 43.02 (26.00) 1.11 
   Serum Creatinine (M, SD) 7.35 (3.65) 6.97 (3.34) 7.74 (3.93) 1.16 
   Phosphorous (M, SD) 4.37 (1.69) 4.12 (1.45) 4.63 (1.88) 1.68 
   Charlson Comorbidity(M, SD) 7.47 (3.14) 7.60 (3.02) 7.33 (3.27) 0.46 
Behavioral risk factors     
  Psychiatric diagnosis 35 (29.2%) 17 (28.3%) 18 (30.0%) 0.04 
  Psychiatric medication 30 (25.0%) 14 (23.3%) 16 (26.7%) 018 
  Substance use history 31 (25.8%) 11 (18.3%) 20 (33.4%) 3.52 
  Positive tox screen 11 (9.2%) 4 (6.6%) 7 (11.6%) 0.90 
  Past Year Admissions (M, SD) 2.94 (3.06) 2.75 (2.32) 3.13 (3.67) 0.68 
Cognitive risk factors     
   Delirium 37 (30.8%) 17 (28.3%) 20 (33.3%) 0.35 
   Positive head imaging 61 (50.8%) 29 (48.3%) 32 (53.3%) 0.30 
   History of seizures 14 (11.7%) 6 (10.0%) 8 (13.3%) 0.32 
   History of hypoxia 19 (15.8%) 6 (10.0%) 13 (21.6%) 3.06 
   Dementia 5 (4.2%) 2 (3.3%) 3 (5.0%) 0.21 
   Stroke history 10 (8.3%) 4 (6.7%) 6 (10.0%) 0.44 
   Cognitive impairment  20.5 (4.50) 20.5 (4.79) 20.4 (4.22) -0.05 
Baseline Assessment     
   REALM-R (M, SD) 5.22 (2.62) 5.29 (2.50) 5.15 (2.75) -0.29 
   REALM-SF (M, SD) 5.46 (2.11) 5.51 (2.02) 5.42 (2.22) -0.23 
   Social Support (M, SD) 2.93 (1.00) 2.92 (0.95) 2.94 (1.06) 0.11 
   Adherence (M, SD) 2.38 (0.60) 2.38 (0.57) 2.38 (0.64) -0.03 
   Depression (M, SD) 6.78 (4.59) 6.88 (4.26) 6.69 (4.94) -0.22 
   Anxiety (M, SD) 5.29 (4.56) 5.22 (4.13) 5.17 (5.00) -0.39 
Note.  Consultation and control conditions did not differ significantly (p < .05) on 
any of the variables in the table. 
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 Main Analyses 
The 30-day readmission rate for the total sample was 26% (31 patients). As 
shown in Table 2, there was a marginally lower early readmission prevalence in the 
consultation (20%) than TAU condition (32%; χ2 = 2.13, p = .077, NNT = 9). 
The rate for the presence of any unplanned return hospital visit within 30 days 
(including inpatient readmissions, emergency department visits, and observation status) 
was 39% (47 patients). The occurrence of any early hospital return visit was significantly 
lower in the consultation (32%) than TAU condition (47%; χ2 = 2.83, p = .046, NNT = 
7). More specifically, there were 9 more patients with inpatient readmissions in the 
control condition than in the family consultation condition (27 vs. 14) and 4 more 
patients with an ED visit (13 vs. 9). There were 3 patients with only observation visits in 
each group. 
For three patients in the treatment group, the intervention could not be completed 
because we failed to contact a support person for the patient; two of those three were 
readmitted within 1 month. Excluding these three patients for the per protocol analyses 
slightly enhanced the condition effects noted above. As shown in Table 3, when those 
three patients were removed from the analyses, the readmission rate was significantly 
lower in the treatment group (18%) than in the control group (32%; p = .039; NNT = 7). 
Next, readmission rates were lower in the treatment group (28% vs. 47%) when 
observation and emergency department visits were added into the equation (p = .019; 
NNT = 6). 
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Table 2. Main Effect of Condition Assignment on 30-Day Readmissions and 
Hospital Visits: Intent-to-Treat 
 Total Sample  
(n = 120) 
Family  
Consultation  
TAU Control  
 
χ2  p  
Intent to Treat 
Analyses 
 (n = 60) (n = 60)  
30-Day Readmit 47 (39%) 12 (20.0%) 19 (31.7%) 2.13 .077 
30-Day Any Return Visit 73 (61%) 19 (31.7%) 28 (46.7%) 2.83 .046 
Per Protocol Analyses  (n = 57) (n = 60)  
30-Day Readmit 31 (26%) 10 (17.5%) 19 (31.7%) 3.13 .039 
30-Day Any Return Visit 89 (74%) 16 (28.1%) 28 (46.7%) 4.31 .019 
 
The 3-month readmission rate for the total sample was 45% (66 patients). As 
shown in Table 3, the consultation condition (40%) and the TAU condition (50%; χ2 = 
1.21, p = .141) did not statistically differ on readmission rates. The rate for the presence 
of any unplanned return visit within 3 months was 61%. For this outcome variable, 
readmission rates were marginally lower in the consultation condition (55%) and the 
TAU control (67%; χ2 = 1.71, p = .075). 
Table 3. Main Effect of Condition Assignment on Readmissions and Hospital 
Visits at Three Months  
 Total Sample  
(n = 120) 
Family  
Consultation  
TAU Control  
 
χ2  p  
Intent to Treat Analyses  (n = 60) (n = 60)  
3 Month Readmit 54 (45%) 24 (40%) 30 (50%) 1.21 .141 
3 Month Any Return Visit 73 (61%) 33 (55%) 40 (67%) 1.71 .075 
 One month follow up: Self-Report Measures 
We retained 84 patients (70%) for 1-month follow up measures of social support, 
adherence, depression, and anxiety. The remaining patients were unable to be reached by 
phone, and did not respond by mail. First, completers (n = 84) and non-completers (n = 
36) were compared across all baseline variables. The only significant difference between 
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groups was that completers were younger than non-completers (t = 2.06, p = .041). Of the 
completers, 43 were from the consultation condition, and 41 were from the control group; 
non-completion was unrelated to experimental condition. 
As shown in Table 4, there was no difference in change in social support, 
adherence, depression, or anxiety between conditions. Furthermore, social support, 
adherence, depression, and anxiety were meant to be examined as potential mediators of 
the intervention but were ruled out because the change in these variables at one month 
was not correlated with the main outcomes. 
Table 4. Change in Self-Report Measures Between Groups at One Month Follow-up 
 Total 
n = 84 
Family 
Consult  
n = 43 
Control 
Group 
n = 41 
F p 
Social Support 
Baseline M (SD) 
2.83 (1.08) 2.87 (0.99) 2.79(1.17)  
 
 
0.19 
 
 
 
.662 
Social Support  
1 month M (SD) 
2.94 (0.95) 3.02 (0.90) 2.85 (1.01) 
Social Support 
Change M (SD) 
0.11 (1.04) 0.16 (0.75) 0.06 (1.28) 
Adherence 
Baseline M (SD) 
2.41 (0.59) 2.36 (0.57) 2.45 (0.63)  
 
 
0.01 
 
 
 
 
.921 
Adherence  
1 month M (SD) 
2.54 (0.50) 2.49 (0.45) 2.60 (0.54) 
Adherence 
Change M (SD) 
0.14 (0.52) 0.13 (0.53) 0.14 (0.51) 
Depression 
Baseline M (SD) 
6.73 (4.67) 7.03 (4.38) 6.41 (5.00)  
 
 
2.32 
 
 
 
.132 
Depression 1 
month M (SD) 
5.60 (4.69) 6.56 (4.90) 4.59 (4.23) 
Depression 
Change M (SD) 
-1.14 (4.09) -0.48 (4.29) -1.82 (3.79) 
Anxiety  
Baseline M (SD) 
4.99 (4.52) 5.04 (4.35) 4.93 (4.75)  
 
 
0.60 
 
 
 
.441 
Anxiety 
1 month M (SD) 
4.41 (5.05) 4.81 (5.30) 4.00 (4.81) 
Anxiety  
Change M (SD) 
-0.58 (4.04) -0.24 (3.77) -0.93 (4.32) 
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 Other variables that predicted readmissions 
  Comorbidities 
As shown in Table 5, history of delirium (χ2 = 11.29, p = .001) and history of 
positive head imaging (χ2 = 6.78, p = .009) were both cognitive risk factors that 
significantly predicted early readmissions.  
  Baseline Variables 
As shown in Table 5, there was a trend such that women were marginally more at-
risk for an early readmission than men (p = .061). The MoCA was the only baseline 
measure that predicted readmissions (p = .015). Baseline social support, adherence, 
depression, anxiety, and health literacy did not predict readmissions across groups. 
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Table 5. Relationship of Baseline Variables with Presence of 30-Day Readmission 
 Variable Total 
N = 120 
Readmit 
n = 31 (25.8%) 
No Readmit 
n = 89 (74.2%) 
t or χ2 
Demographics     
   Age (M, SD) 57.5 (14.4) 60.32 (14.8) 56.5 (14.2) -1.27 
   Gender (Male) 60 (50%) 11 (35.5%) 49 (55.1%) 3.52† 
   Gender (Female) 60 (50%) 20 (64.5%) 40 (44.9%) 3.52† 
   Race = Black 103 (85.8%) 29 (93.5%) 74 (83.1%) 2.21 
   Race = White 15 (12.5%) 2 (6.5%) 15 (16.9%) 
   Grade > 12th 51 (42.5%) 15 (48.4%) 36 (40.4%) 0.59 
Medical risk factors     
   CHF 58 (48.3%) 18 (48.4%) 40 (44.9%) 1.59 
   Smoking 71 (59.2%) 16 (51.6%) 55 (61.8%) 0.99 
   Diabetes 74 (61.7%) 19 (61.2%) 55 (61.8%) 0.00 
   Hypertension 118 (98.3%) 29 (93.5%) 89 (100.0%) N/A 
   COPD 22 (18.3%) 5 (16.1%) 17 (19.1%) 0.14 
   Blood Urea Nitrogen 40.72 (22.65) 36.68 (20.87) 42.12 (23.19) 1.15 
   Serum Creatinine 7.35 (3.65) 6.84 (3.72) 7.53 (3.62) 0.92 
   Phosphorous 4.37 (1.69) 4.27 (1.92) 4.41 (1.62) 0.38 
   Charlson Index 7.47 (3.14) 8.32 (2.98) 7.17 (3.15) 1.78 
Behavioral risk factors     
  Psychiatric diagnosis 35 (29.2%) 9 (29.0%) 26 (29.2%) 0.00 
  Psychiatric medication 30 (25.0%) 6 (19.4%) 24 (27.0%) 0.71 
  Substance use history 31 (25.8%) 9 (29.0%) 22 (24.7%) 0.22 
  Positive tox screen 11 (9.2%) 4 (12.9%) 7 (7.9%) 0.70 
  Past Year Admissions 2.94 (3.06) 3.94 (4.32) 2.60 (2.42) -1.64 
Cognitive risk factors     
   Delirium 37 (30.8%) 17 (54.8%) 20 (22.5%) 11.29** 
   Positive head imaging 61 (50.8%) 22 (71.0%) 39 (43.8%) 6.78** 
   History of seizures 14 (11.7%) 4 (12.9%) 10 (11.2%) 0.06 
   History of hypoxia 19 (15.8%) 6 (19.4%) 13 (14.6%) 0.39 
   Dementia 5 (4.2%) 2 (6.5%) 3 (3.4%) 0.55 
   Stroke history 10 (8.3%) 4 (12.9%) 6 (6.7%) 1.14 
   MoCA Total 20.47 (4.50) 18.79 (5.66) 21.06 (3.88) 2.47* 
Baseline Assessment     
   REALM-R 5.22 (2.62) 5.10 (2.92) 5.26 (2.52) 0.27 
   REALM-SF 5.46 (2.11) 5.24 (2.37) 5.58 (2.01) 0.97 
   Social Support 2.93 (1.00) 3.01 (0.97) 2.91 (1.02) -0.47 
   Adherence 2.38 (0.60) 2.45 (0.59) 2.35 (0.60) -0.79 
   Depression 6.78 (4.59) 6.52 (4.10) 6.88 (4.77) 0.38 
   Anxiety 5.29 (4.56) 4.06 (4.14) 5.58 (4.66) 1.61 
Note. † < .10 *p <.05, ** p<.01; N/A – does not meet criteria for Chi Square test 
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  Therapist Post-Session Ratings 
The therapist session ratings were analyzed in an exploratory fashion of predictors 
of readmissions within the family meeting condition. Only one item (“seemed to 
appreciate the consult”) predicted lower risk of an early readmission (t = 2.26, p = .046). 
 Moderation Analyses 
 There was a trend of a moderation that the intervention worked better for patients 
with higher baseline MoCA scores, but the effect failed to reach significance (p = .116).  
In the consultation condition, readmitted patients had numerically lower cognitive 
functioning scores (M  = 16.8, SD = 6.6) than patients who were not readmitted (M = 
21.4, SD = 3.8), whereas, in the control group, cognitive functioning scores were similar 
for patients who were (M  = 20.0, SD  = 4.7) and were not (M  = 20.6, SD  = 4.0) 
readmitted. There was also a trend that the intervention worked better for patients with no 
history of substance abuse (n = 89), but the effect failed to reach significance (p = .105). 
In patients without a history of substance abuse (n = 89), there was a lower readmission 
rate in the family consult group (16%) versus the control group (35%; p < .042). In the 31 
patients with a history of substance use, the readmission rate was surprisingly 
significantly higher (p = .042) in the treatment group (36%) versus the control group 
(25%). Gender and method of contact for the intervention (in person versus phone) did 
not moderate the efficacy of the intervention. 
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CHAPTER 4 DISCUSSION 
 A brief behavioral intervention—consulting with the patients’ family members 
about the patient’s cognitive status and other risk factors and the need for better 
medication adherence—reduces early hospital readmissions and all unplanned hospital 
visits among patients with ESRD. Many patients with ESRD are at substantial risk for 
early readmission, particularly due to cognitive impairment, low health literacy, and 
subsequent nonadherence to medications and dialysis. Intervening with family members 
in a manner that addresses these deficits reduces the likelihood of early readmission.  
The effect size of this family consultation on early readmissions (reducing early 
readmissions from 32% to 20%) was clinically significant. The effect size (NNT) 
obtained in this study suggests that only 6 or 7 patients need to receive this consultation 
to reap the benefits of one patient avoiding an early readmission. We can find no other 
study demonstrating a comparable reduction in readmission rates in patients with ESRD. 
On a practical level, the brevity and simplicity of the intervention means that an effect 
size of the magnitude achieved in this study would be more than enough for the savings 
of this intervention would outweigh its costs.  In this case, a psychology doctoral student 
conducted the initial assessment, which required about 20 minutes to obtain data on 
cognitive impairment, health literacy, and social support, and then less than 10 minutes, 
on average, to provide the consultation. Including time for note writing and chart review, 
the actual billing in most medical settings would be for one hour, with an estimated cost 
of $220 for a psychologist in this setting. The average cost per inpatient day in Michigan 
is $2132 dollars, with a median length of stay of 4.0 days, and the average cost of an 
emergency room visit is $1233 (Kshirsagar, Hogan, Mandelkehr, & Falk, 2000). Thus, 
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the total net savings of this intervention are roughly estimated to be at $81,752 for this 
sample (n = 60), or an average of over $1200 per patient. Beyond the economics, 
however, are the benefits of improving the health outcomes of substantial numbers of 
patients. 
Notably, this trial has substantial generalizability or external validity in that it 
excluded few patients, was conducted with high feasibility—at bedside or via 
telephone—and did not rely on special resources or high involvement from other 
providers within the nephrology unit. Furthermore, the sample was one that is often 
viewed as particularly high risk: urban, largely African American patients, with multiple 
social, economic, and behavioral risk factors. Therefore, we believe that this intervention 
can readily be implemented on other nephrology units, and perhaps other hospitalized 
populations with chronic disease and high risk for readmission. 
Additionally, I believe that the impact of the intervention was likely attenuated by 
the lack of integration of the psychologist consultant with the rest of the team in the 
nephrology unit. Integrated care has been identified as a key predictor of success in 
behavioral health interventions; therefore, we expect that a greater reduction in early 
readmissions might occur if the psychologist worked more closely with other providers 
on the unit, attended interdisciplinary care meetings, and documented behavioral 
medicine notes in the EHR (Bridges et al., 2015; Crosson, 2009).  
It is disconcerting that this basic assessment and family consultation rarely 
happens in hospitals. Many patients and family members in this trial remarked that no 
one had ever explained to them that cognitive impairment was common in patients with 
ESRD, and that such impairment puts them at risk for missing medications and dialysis 
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treatments, resulting in further hospital care. In addition, some patients reported some 
mistrust of their providers, which is consistent with the literature on difficult patient-
provider relationships in patients with chronic illnesses (Kammerer, Garry, Hartigan, 
Carter, & Erlich, 2007). With these concerns in mind, it is imperative that providers listen 
to patients’ concerns, assess their risk factors, engage the family in the patient’s health 
care, and build trust to increase their motivation to follow through on discharge 
recommendations. More research is need to determine how to address this issue, which 
could result in substantial improvement in care both in patients with ESRD and in the 
national healthcare system in general. 
This study was designed with an effectiveness rather than efficacy framework, 
and thus did not rely on special conditions, resources, or even above average levels of 
cooperation from other providers within the nephrology unit. Therefore, we believe that 
this same intervention could easily be implemented on any nephrology unit. We believe 
that effectiveness studies are an especially important step in translating research into 
clinical practice (Glasgow, Lichtenstein, & Marcus, 2003). There is already an abundance 
of trials demonstrating the efficacy of behavioral health interventions in medical 
populations such as congestive heart failure and liver disease, but there remains a lack of 
implementation (Brownson, Colditz, & Proctor, 2012). 
 One limitation of this study is that we do not know which social, emotional, or 
behavioral changes family members and patients might have made after the consultation 
that reduced early readmission rates. Our hypotheses that the family meetings improved 
adherence by way of social support compensating for patient cognitive impairment or 
poor health literacy was not supported by the 1-month follow up self-report measures.  
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The findings (or lack thereof) in the previous paragraph require some explanation. 
One possibility is that our assessment measures for social support and adherence may 
have had shortcomings in terms of their validity. For social support, it would have been 
useful to obtain reports from the family members who participated in the meeting, 
because it was their behavior that we were actually intending to change. This also would 
have been useful for a manipulation check about the success of the psychoeducation 
piece of the meeting. For adherence, we were working with patients with cognitive 
impairment and a low education level. Therefore, by definition we know that they are 
likely to be poor historians when reporting on their ability to take their medications on 
time. More accurate measures of adherence such as electronic pill-boxes or records of 
dialysis attendance would have been preferable. Overall, the limitations of these 
assessment measures prevented us from drawing meaningful conclusions regarding the 
mechanisms of change in this intervention. 
Therefore, we suspect that the consultation led the family member or support 
person to help patients remember to take their medications, even though the self-reported 
adherence and social support scores in this study do not support this. More than half of 
the patients with ESRD in the nephrology inpatient population have some cognitive 
impairment, so it is not surprising that they have difficulty with medication adherence. 
Although willful nonadherence to the treatment regimen may occur for some patients 
with ESRD, cognitive deficits remain woefully undetected and unmanaged when 
discharge planning, and these impairments appear to be a key factor in early hospital 
readmissions (Jasinski et al., in press). Furthermore, most of the patients in this sample, 
and many of those with ESRD in general, come from disadvantaged socioeconomic 
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backgrounds. We believe that this family consultation raises awareness of barriers to 
adherence such as cognitive impairment and low health literacy, and encourages support 
people to help patients compensate—and the patient to accept the help—for these 
challenges. We believe that this family consultation raises awareness of barriers to 
adherence such as cognitive impairment and low health literacy, and allows support 
people to help patients compensate for these challenges. 
The lack of significant moderating variables suggests that this intervention would 
be effective across a wide range of patients. However, there were two trends that merit 
comment. It was surprising that patients with less cognitive impairment seemed to benefit 
more from the intervention than those with more severe CI. Perhaps instead of this 
intervention working by family members compensating for patients who were incapable 
of caring for themselves, this intervention works best through family members helping 
patients who still have some ability to actively participate in their care and coordinate 
ways that their support people can help them adhere to their medication regimen. Second, 
although the moderation did not reach significance, it appeared that the intervention may 
have worked better in patients with no substance abuse history. This intervention did not 
target substance abuse, and therefore the same rate of reduction in readmissions may not 
occur with patients who are actively using. It is possible that substance use overrides any 
benefits that might be obtained by improved adherence. 
Patient-Provider Relationships 
 These results have implications for the issue of patient-provider relationships. 
There has been a robust literature linking better patient-provider relationships with better 
treatment adherence. The idea is that when patients trust their providers more, they are 
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more likely to follow through on recommendations (Ciechanowski, Katon, Russo, & 
Walker, 2001). Although it might seem that trusting one’s provider should be automatic, 
our fragmented healthcare system has created situations where providers have little time 
to actually speak to patients (Nam, Chesla, Stotts, Kroon, & Janson, 2011). This has led 
to many patients having a great deal of frustration, as the healthcare system often does 
not meet their expectations (Naidu, 2009).  
There are several reasons why patient-provider relationships for patients with 
ESRD are particularly at-risk for being troublesome. First, research has shown a negative 
correlation between the complexity of the condition that a patient has and their 
relationship with their physician (Porcerelli, Murdoch, Morris, & Fowler, 2014). Patients 
with ESRD are often the most complex cases within the health care system; therefore, it 
is not surprising that the problem is so glaring in this population. Second, there is a 
stigma about having ESRD, given that the disease usually results from long-term 
unmanaged diabetes and hypertension or substance abuse (Hopper, 1981). Therefore, 
there is a belief that these patients are responsible for their declining health, and they are 
often reported as being “difficult” to work with. Third, patients with ESRD are 
disproportionately represented by low SES African Americans, whereas their physicians 
are more likely to be high SES people of European, Middle Eastern, or Asian descent 
(Smedley, Stith, & Nelson, 2003). Sometimes, these significant differences in 
demographics can breed mistrust on the side of the patient. 
Although the problems with patient-provider relationships may sound grim, the 
identification of this problem represents an opportunity for improved care. In fact, it is 
possible that one of the mechanisms of success of this intervention was through 
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increasing the trust of patients and their support people support people in the treatment 
team. As part of the protocol, the researcher spoke to the patients and listened to their 
concerns, which unfortunately is not something that these patients always encounter. 
Therefore, it may be that the improved trust might motivate patients to adhere to their 
treatment plans. Future research should consider the patient-provider alliance as a 
mediator for this type of intervention. 
Iatrogenic Effects of Medicine 
 Another important reason for decreasing hospital utilization is that there are often 
iatrogenic effects of hospital stays. For example, there are many infections, such as C. 
Difficile that are common in hospitals, but patients would rarely be exposed to in their 
daily lives (Hidron et al., 2008). Additionally, the rate of mistakes by healthcare 
providers is higher than most people would expect (Naveh, Katz-Navon, & Stern, 2005). 
In our country, there is a misconception that hospitals are places of healing, when in 
reality patients are much safer at home, and hospitals should only be used when totally 
necessary (Lafont, Gérard, Voisin, Pahor, & Vellas, 2011). Yet, the effect of the 
intervention implies a fundamental lack of attention to discharge planning that would 
seem to be common sense to most people. With the results of this study exposing these 
simple flaws in our healthcare system, there will be a greater understanding in public 
perception regarding the risks of hospitalization. 
Socio-Economic Status 
 Socio-economic status is an issue that factors into the health behaviors of patients 
with ESRD. This sample of this study would not be appropriate for testing the 
moderating effects of SES, given that the same was relatively homogenous with mostly 
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low-income, inner-city African Americans. However, the results demonstrate that an 
intervention based on psychoeducation can be effective within this population. These 
patients generally had below average health literacy, and the fact that the intervention 
was able to work in spite of this is promising. It will be important to continue to develop 
and test interventions that work with low SES populations, in order to reduce the health 
disparities nationwide (Goldman & Smith, 2002). 
Cognitive Impairment as a Predictor of Readmissions 
 Hypotheses were confirmed that three indicators of cognitive impairment were 
predictive of early readmissions: delirium, positive head imaging, and low scores on the 
Montreal Cognitive Assessment. No other biological/medical risk factors (such as serum 
creatinine or BUN) predicted early readmissions. There were fewer baseline predictors of 
readmissions than we expected, although it is possible that the effect of the intervention 
might have diluted some of these effects. Although this type of study is novel within the 
kidney disease population, the findings are consistent with a growing cardiology 
literature showing that cognitive impairment is one of the key factors in early hospital 
readmissions, but is often ignored in medical settings (Cameron et al., 2010; Dodson et 
al., 2013; Huijts et al., 2013; Ketterer, Draus, et al., 2014; McLennan, Pearson, Cameron, 
& Stewart, 2006; O'Donnell et al., 2012). Finally, in addition to confirming that cognitive 
impairment predicts early readmissions, the results demonstrated that it is possible to 
identify patients who are at risk and intervene in a way that compensates for cognitive 
deficits to actually prevent readmissions. 
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Limitations 
First, our outcome measure did not account for readmissions or hospital visits to 
external health care systems. This means that there might be some missing readmissions 
in our tally, which would skew our main outcome data, and not be consistent with the 
method that CMS uses for calculating readmission penalties. However, through phone 
conversations with patients at follow up, we have reason to believe that such external 
readmissions were rare, and that they would be randomly distributed across experimental 
conditions even if they did occur.  
Second, only one psychologist was used to conduct the family meetings. The 
literature has shown that the individual ability of therapists can have a major impact on 
outcomes, but we did not have other consultants available (Crits-Christoph & Mintz, 
1991). Therefore, it is possible that other psychologists might have different levels of 
success with this intervention. Yet, the therapist’s level of training (master’s degree) and 
supervision in this study are roughly consistent with what might be expected from 
providers administering this intervention in real world settings. Therefore, generalization 
to other consultants would need to be demonstrated in replication studies. 
Next, specific reasons for readmission are complex and not well delineated in 
medical records.  These patients are generally very ill, and linking the intervention to 
changes in adherence or family relations, and subsequently to health changes needs 
further study. Finally, it is likely that this intervention is most effective with subsets of 
patients, such as those with a certain degree of cognitive impairment or certain types of 
family relations, but our sample was not large enough to reliably test such moderators. 
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In terms of the implementation of the intervention, we were limited by the 
inability to contact support people for three patients. However, this likely reflects the 
reality of clinical practice; overall, we were pleased with the overall rate of contact with 
support people. Similarly, we would have preferred to have conducted more of the 
interventions face-to-face. Again, it was important to prioritize completing the 
intervention over its location, so conducting a portion of them over the phone was 
expected. However, it is possible that if the intervention were a routine part of the 
standard of care, that more could have been conducted at bedside. 
Conclusions 
The results of this study represent the potential for a “win-win” scenario; an 
intervention that improves patient care while reducing health care expenditures. 
Therefore, there is a compelling argument for rapidly moving forward to promote and 
disseminate such interventions of this nature. The next objective would be to run a 
replication study with a methodology that addresses the aforementioned limitations and 
greater integration with the rest of the health care team. From a long-term perspective, 
these results support greater involvement of behavioral medicine in treatment planning. 
This intervention was carried out by a graduate student in clinical psychology, who was 
supervised by a senior clinical health psychologist. Therefore, we believe that this 
intervention could be implemented by mid-level providers such as physician assistants, 
nurses, and social workers, who are trained and supervised by a health psychologist. 
Additionally, episodic, longer term follow-up may be necessary in order to maintain the 
benefits of the intervention. We also think that this same type of family meeting will be 
successful with other populations of inpatients with chronic diseases where cognitive 
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impairment is common, such as congestive heart failure or liver disease. As our national 
health care system shifts from a fee-for-service based model to one that is focused on 
value, interventions such as this one will become increasingly vital. 
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APPENDIX A. STUDY DETAILS 
FAMILY CONSULT PROTOCOL 
 
1) Introductions: 
a. Introduce self and obtain names of support people present and their 
relationship to the patient. 
b. Make efforts to establish rapport and trust. 
2) Rationale 
a. Friends and family can make a major difference for patients with ESRD in 
terms of health and quality of life. 
b. Non-threatening language such as “improving stress and coping” to cite 
rationale for study 
c. Patients on dialysis have a high rate of being in and out of the hospital 
over and over. The goal is to keep you healthy and out of the hospital. 
3) History 
a. Review patient/family understanding of events that caused the hospital 
admission 
b. Empathize with frustration about the burden that their care requires (costs, 
travel, side effects, insurance, etc.) 
c. To patient: Many patients on dialysis say that they feel burdened by all of 
the things they need to do to take care of their health. Do you ever feel 
that way? 
d. To support: How aware are you of the effort [patient] puts in to manage 
the ESRD condition? 
e. Assess how involved the support people currently are in terms of 
managing ESRD 
4) Medications 
a. Have patient do clock draw so support people can observe (Goal is to 
make support people aware of the severity of cognitive impairment) 
b. Discuss practicality of support people helping with medication adherence. 
c. Recommend use of pillbox, and assess how patient refills medications. 
5) Cognitive Impairment 
a. Explain how risk of “forgetfulness” or “confusion” increases with renal 
failure. 
b. “Blame the illness or medications” for these symptoms, in order to avoid 
stigmatization 
c. Assess subjective experience of cognitive impairment, from patient and 
support people perspective. 
d. Discuss findings from baseline cognitive screening. 
e. Explain the cognitive symptoms, and how family/friends might notice it 
before the patient. 
6) Wrap Up 
a. Offer to answer any other questions. 
b. Help direct patient and family member to appropriate member of medical 
staff if I cannot answer the question. 
c. Ask participants to reflect on the meeting 
7) As needed: Motivational Interviewing Techniques 
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a. Throughout the meeting, be mindful of stage of change for both patients 
and support people in terms of health behaviors (especially medications) 
b. Roll with patients/families who display resistance, and/or those in the pre-
contemplative stage of change 
c. Pros and Cons technique 
d. Explore barriers to social support collaboration to medication adherence 
and communication with patient. 
e. Remind participants that the decision is theirs 
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CONSENT FORM 
 
Mark W. Ketterer, PhD 
Henry Ford Hospital/A2 
2799 West Grand Boulevard 
Detroit, MI 48202 
 
1. WHY IS THIS RESEARCH BEING DONE?    
 
        To make reading this consent form easier, the word “you” refers to you throughout the 
consent form. 
 
        You have been asked to take part in a research study because you have spent time as an 
inpatient in the Nephrology unit at Henry Ford Hospital.  The purpose of this research study 
is to determine how talking about your health care with a family member or friend influences 
your health.  
 
       There will be approximately 150 people in this research study at Henry Ford Health 
System (HFHS).  
 
2. WHAT WILL HAPPEN IF I TAKE PART IN THIS RESEARCH STUDY? 
 
There will be two groups in the study. The group you are assigned to will be chosen by chance 
(like flipping a coin). 
 
Your participation in this study will last up to one month after your discharge from the hospital.  
As part of this study, you will have no additional visits to the clinic, but will be visited by our 
research staff once or twice during your hospital stay, and once after your discharge. 
 
At visit 1, you will have the following procedures:  
 
Extra and not experimental:   
• Your records will be reviewed for events that might affect your cognitive status, and your 
family member may be asked if we may proceed with following you for the study.   
• You will be asked to complete a series of simple cognitive task in questionnaire form 
• We estimate the time commitment for you at 20 minutes. 
 
At visit 2, you will have the following procedures:  
  
Extra and experimental:   
• Within a few days of visit 1, and before you are discharged, we may have a discussion 
with you and one or more of your family members or friends about how to take care of 
your chronic illness at home.  
• We estimate the time commitment for you and your family member at 45 minutes.     
• This visit applies to only 1 of the 2 randomly assigned groups in the study. 
 
 
At visit 3, you will have the following procedures:  
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Extra and experimental: One month after your discharge from the hospital, we will contact 
you or your family member by phone to ask a few questions about the self-management of 
your chronic illness. We estimate the time commitment for you and your family member at 15 
minutes.     
  
3.  WHAT ARE THE RISKS OF THE STUDY? 
 
        You should tell the person obtaining your consent about any other medical research 
studies you are 
     involved in right now. 
 
      It is not expected that you will have any complications or discomforts from being in this 
study. There 
    may be risks or discomforts that are not known at this time.   
 
 
4. WHAT ARE THE BENEFITS TO TAKING PART IN THE STUDY? 
 
      The benefits of participating in this study may include: helping you with self-management 
of your illness. You may not be helped by participating in this study. However, others may be 
helped by what is learned from this research. 
 
 
5. WHAT OTHER OPTIONS ARE THERE? 
 
            You do not have to participate in this study. Your other choices may include: 
• Getting treatment or care for kidney disease without being in a study, such as the routine 
care in the Nephrology unit that does not involve meetings with family members or 
friends. 
• Taking part in another study 
• Getting no treatment 
 
      Talk to your doctor about your choices before you decide if you will take part in this 
study. 
 
 
6. WHAT ABOUT CONFIDENTIALITY? 
 
By signing this consent form, you agree that we may collect, use and release your personal 
and health information for the purpose of this research study.   
 
We may collect and use: 
• Your existing medical records. 
• New health information created during this study. 
• Health insurance and other billing information. 
 
We may release this information to the following people: 
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• The Principal Investigator and his/her associates who work on, or oversee the 
research activities. 
• Government officials who oversee research (Food and Drug Administration). 
• Your insurance company or others responsible for paying your medical bills.  
• Other researchers at other institutions participating in the research. 
 
Once your information has been released according to this consent form, it could be released 
again and may no longer be protected by federal privacy regulations. 
 
This consent form, test results, medical reports and other information about you from this 
study may be placed into your medical record. Generally, you are allowed to look at your 
medical record.  During the research study, you will be allowed to look at your research study 
information that is not in your medical record. 
 
HFHS or others may publish the results of this study.  No names, identifying pictures or other direct identifiers will be used 
in any public presentation or publication about this study unless you sign a separate consent allowing that use. 
 
This consent to use and release your personal and health information will expire at the end of this research study.  
 
You do not have to sign this consent to release your medical information and may cancel it at 
any time. If you decide not to sign this consent or cancel your consent, you cannot participate 
in this study. If you notify us that you wish to stop participating in this study, we may 
continue to use and release the information that has already been collected.  To cancel your 
consent, send a written and dated notice to the principal investigator at the address listed on 
the first page of this form.  
  
A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as 
required by U.S. Law.  This web site will not include information that can identify you.  At 
most, the Web site will include a summary of the results.  You can search this Web site at any 
time.  
 
7. WHAT IF I AM INJURED? 
 
   There is no federal, state, or other program that will compensate you or pay for your 
medical care if you are injured as a result of participating in this study.  You and/or your 
medical insurance may have to pay for your medical care if you are injured as a result of 
participating in this study. You are not giving up any of your legal rights by signing this 
consent form. 
 
8. WHO DO I CALL WITH QUESTIONS ABOUT THE STUDY OR TO REPORT 
AN INJURY?  
 
Mark W. Ketterer, or his staff member has explained this research study and has offered to 
answer any questions.  If you have questions about the study procedures, or to report an 
injury you may contact Dr. Ketterer at (734-642-8776). Medical treatment is available to you 
in case of an injury. 
 
If you have questions about your rights as a research subject you may contact the Henry Ford 
Health System IRB Coordinator at (313) 916-2024. The IRB is a group of people who review 
the research to protect your rights. 
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9.  DO I HAVE TO PARTICIPATE IN THIS STUDY? 
 
   No, your participation in this research study is voluntary.  If you decide to participate, you 
can stop at any time. If this happens, you may be asked to return for a visit for safety reasons.  
You will get the same medical care from HFHS whether or not you participate in this study. 
There will be no penalties or loss of benefits to which you would otherwise be entitled if you 
choose not to participate or if you choose to stop your participation once you have started. 
You will be told about any significant information that is discovered that could reasonably 
affect your willingness to continue being in the study. 
 
 
10. WHO ELSE CAN STOP MY PARTICIPATION? 
 
   The Principal Investigator, sponsor or your doctor can end your participation in the research 
study at any time.  If this happens, you may be asked to return for a visit for safety reasons.   
 
11. WILL IT COST ANYTHING TO PARTICIPATE? 
 
   We do not expect there to be any additional costs to you if you participate in this study. 
Items related to the routine medical care that you would receive even if you did not 
participate in this study will be billed to you or your insurance company. You have the right 
to ask what it will cost you to take part in this study.  
 
12. WILL I BE PAID TO PARTICIPATE?  
 
   You will be paid $20 after completing the first set of questionnaires, and $20 after 
completing the follow-up phone call. If you complete the study, you will be paid a total of 
$40. If you do not finish the study, you will be paid for the part that you did complete. 
 
13. CONSENT 
   You have read this consent form or it has been read to you.  You understand what you are 
being asked to do.  Your questions have been answered.  Any technical terms you did not 
understand have been explained to you.  You agree to be in this study.  You will be given a 
copy of this consent form.  
 
__________________________________________           _______________     
Signature of Subject                                                               Date                  Time 
 
__________________________________________            
Print Name of Subject                                                             
 
__________________________________________           _______________     
Witness to Signature            Date                          Time           
 
__________________________________________            
Print Name of Person Obtaining Consent                                                            
 
__________________________________________           _______________     
Signature of Person Obtaining Consent          Date                          Time           
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__________________________________________           _______________     
Signature of Person Signing For Subject                                Date                  Time 
 
__________________________________________ 
Print Name of Person Signing for Subject and Relationship to Subject*  
 
__________________________________________            
Print Name of Subject                                                             
 
__________________________________________           _______________     
Witness to Signature            Date                          Time          
    
 
__________________________________________           _______________     
Signature of Person Obtaining Consent          Date                          Time           
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APPENDIX B. MEASURES 
MONTREAL COGNITIVE ASSESSMENT 
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REALM
 
REALM-R Examiner Record 
 
 
 
 
 
 
 
 
Patient Name/
Subject # ____________________________________________  Date of Birth __________________ 
 
Date ________________  Clinic _________________________________  Examiner _______________________________________ 
Reading 
Level           _____________ 
 
Grade 
Completed  _____________ 
 
 
 
 
fat fatigue  ____ 
  
flu directed  ____ 
  
pill colitis  ____ 
  
allergic ____ constipation ____ 
  
jaundice ____ osteoporosis ____ 
  
anemia ____ 
 
 
 
 
 
 
Fat, Flu, and Pill are not scored.  We have previously 
used a score of 6 or less to identify patients at risk for 
poor literacy.  
 
 
 
 
Score ______ 
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REALM-SF Form 
Patient name ___________________ Date of birth__________________ Reading level________ 
 
Date ________________ Examiner ______________________  Grade completed ___________ 
 
Menopause  
Antibiotics  
Exercise  
Jaundice  
Rectal  
Anemia  
Behavior  
 
 
Instructions for Administering the REALM-SF 
1. Give the patient a laminated copy of the REALM-SF form and score answers on an unlaminated 
copy that is attached to a clipboard. Hold the clipboard at an angle so that the patient is not 
distracted by your scoring. Say: 
 "I want to hear you read as many words as you can from this list. Begin with 
the first word and read aloud. When you come to a word you cannot read, do 
the best you can or say, 'blank' and go on to the next word." 
2. If the patient takes more than 5 seconds on a word, say "blank" and point to the next 
word, if necessary, to move the patient along. If the patient begins to miss every word, 
have him or her pronounce only known words. 
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MSSS-5 
1. How often is someone available to take you to the doctor if you need 
to go? 
_____ None of the time 
_____ A little of the time 
_____ Some of the time 
_____ Most of the time 
_____ All of the time 
2. How often does someone help you take your medications? 
_____ None of the time 
_____ A little of the time 
_____ Some of the time 
_____ Most of the time 
_____ All of the time 
3. How often is someone available to listen to concerns or worries about 
your medical care?  
_____ None of the time 
_____ A little of the time 
_____ Some of the time 
_____ Most of the time 
_____ All of the time 
4. How often does someone help you manage your medical problems? 
_____ None of the time 
_____ A little of the time 
_____ Some of the time 
_____ Most of the time 
_____ All of the time 
5. How often does someone encourage you to eat the right foods? 
_____ None of the time 
_____ A little of the time 
_____ Some of the time 
_____ Most of the time 
_____ All of the time 
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ITAS-M 
 
1. In the last month, how often did you forget to take your medications? 
_____ 0% of the time 
_____ 1-20% of the time 
_____ 21-50% of the time 
_____ More than 50% of the time 
2. In the last month, how often were you careless about taking your 
medications? 
_____ 0% of the time 
_____ 1-20% of the time 
_____ 21-50% of the time 
_____ More than 50% of the time 
3. In the last month, how often did you stop taking your medications 
because you felt worse? 
_____ 0% of the time 
_____ 1-20% of the time 
_____ 21-50% of the time 
_____ More than 50% of the time 
4. In the last month, how often did you miss taking your medications for 
any reason? 
_____ 0% of the time 
_____ 1-20% of the time 
_____ 21-50% of the time 
_____ More than 50% of the time 
 
5. In the last month, how often did you miss your planned dialysis 
sessions for any reason? 
_____ 0% of the time 
_____ 1-20% of the time 
_____ 21-50% of the time 
_____ More than 50% of the time 
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PATIENT HEALTH QUESTIONNAIRE - 8 
 
 
 
 
 
 
 
Personal Health Questionnaire Depression Scale (PHQ-8) 
 
 
Over the last 2 weeks, how often have you been bothered by any of the following problems?  
(circle one number on each line) 
    More than  
How often during the past 2 Not Several half Nearly 
weeks were you bothered by... at all days the days every day 
 
1. Little interest or pleasure in 
 doing things ...................................................... 0 1 2 3 
 
2. Feeling down, depressed, or hopeless .............. 0 1 2 3 
 
3. Trouble falling or staying asleep, or  
 sleeping too much ............................................. 0 1 2 3 
 
4. Feeling tired or having little energy.................... 0 1 2 3 
 
5. Poor appetite or overeating ............................... 0 1 2 3 
 
6. Feeling bad about yourself, or that you  
 are a failure, or have let yourself or  
 your family down ............................................... 0 1 2 3 
 
7. Trouble concentrating on things, such as  
 reading the newspaper or watching  
 television ........................................................... 0 1 2 3 
 
8. Moving or speaking so slowly that other  
 people could have noticed. Or the opposite – 
 being so fidgety or restless that you have  
 been moving around a lot more than usual ....... 0 1 2 3 
 
 
Scoring 
If two consecutive numbers are circled, score the higher (more distress) number. If the numbers are not 
consecutive, do not score the item. Score is the sum of the 8 items. If more than 1 item missing, set the 
value of the scale to missing. A score of 10 or greater is considered major depression, 20 or more is 
severe major depression. 
 
 
 
 
 
	 60	
	
 
GAD-7 
Generalized Anxiety Disorder 7-item (GAD-7) scale 
 
Over the last 2 weeks, how often have you been 
bothered by the following problems?  
Not at 
all sure  
Several 
days  
Over half 
the days  
Nearly 
every day  
1.  Feeling nervous, anxious, or on edge   0   1   2   3  
2.  Not being able to stop or control worrying   0   1   2   3  
3.  Worrying too much about different things   0   1   2   3  
4.  Trouble relaxing   0   1   2   3  
5.  Being so restless that it's hard to sit still   0   1   2   3  
6.  Becoming easily annoyed or irritable   0   1   2   3  
7.  Feeling afraid as if something awful might 
happen  
0   1   2   3  
Add the score for each column   +  +  +    
Total Score (add your column scores) =             
 
If you checked off any problems, how difficult have these made it for you to do your work, take 
care of things at home, or get along with other people? 
 
Not difficult at all __________ 
Somewhat difficult _________ 
Very difficult _____________ 
Extremely difficult _________ 
 
 
Source: Spitzer RL, Kroenke K, Williams JBW, Lowe B. A brief measure for assessing generalized anxiety 
disorder. Arch Inern Med. 2006;166:1092-1097. 
 
 
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Stress and Health Interview  
 Psychologist Post-Treatment Rating Form 
 
Patient ID:    Psychologist:   
 
Date of session:    Start time:  Duration of session (minutes): 
 
Location:    Support Present: 
 
Overall Ratings: 
 
(0 = not at all  1 = a little 2 = moderately 3 = quite a bit 4 = a lot) 
 
___ baseline involvement of support 
___ was interested or motivated to participate  
___ learned the material being taught 
___ was focused on and attentive to the session content (rather than tangential or distracted) 
___ participant / psychologist interactions were positive 
___ developed greater awareness of barriers to adherence 
___ seemed to appreciate the consult 
___ Lives with someone (1 = yes, 0 = no) 
 
 
Session Content Checklist: 
___ Provided rationale  
___ Included reasons why it will benefit the support people for them to help 
___ Reviewed patient/family understanding of events that caused the hospital admission 
___ Empathized with frustration of managing chronic illness 
___ Showed clock draw 
___ Practical issues of support people involvement 
___ Pillbox and medication adherence 
___ Explained how “forgetfulness” can occur with renal failure and medications 
___ Anxiety and/or depression 
___ Substance Abuse 
 
 
 
Additional Comments: 
______________________________________________________________________ 
 
______________________________________________________________________ 
 
______________________________________________________________________ 
 
______________________________________________________________________ 
 
______________________________________________________________________ 
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Background: The U.S. Centers for Medicare and Medicaid Services have mandated 
reducing early hospital readmissions (i.e., within 30 days of discharge) to both improve 
patient care and reduce expenses. Patients with end-stage renal disease (ESRD) have 
relatively high early readmission rates, due in part to their complex medical regimens but 
also cognitive impairment, health literacy problems, and lack of social support. We 
developed a brief family consultation intervention to address these problems and tested 
its ability to reduce early readmissions among patients with ESRD. 
Method: 120 hospitalized adults with ESRD (M age = 57.5 years; 50% male; 86% 
Black, 12% White) were recruited from an urban, inpatient nephrology unit. Patients 
were randomized to family consultation (FC; n = 60) or treatment-as-usual (TAU) control 
(n = 60) conditions. Family consultations, conducted either bedside or via telephone, 
were conducted with 57 of the 60 assigned patients and covered psychoeducation about 
cognitive and behavioral risk factors for readmission and how to compensate for them. 
Blinded medical record review was conducted later to determine readmissions within 30 
days. 
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Results: Chi-square tests and logistic regressions tested intervention effects. Per protocol 
analyses (excluding three FC patients who received no consultation) indicated that FC 
reduced early readmission (18%) after discharge, compared to TAU (32%; χ = 3.13, p = 
.039), and reduced any early hospital return visit (emergency department, brief 
observation, or readmission) compared to TAU (28% vs. 47%; χ = 4.31, p = .019). Intent-
to-treat analyses revealed that FC marginally reduced readmission (20%) compared to  
TAU (32%; χ = 2.13, p = .077), but FC still significantly reduced any hospital visit (32%) 
compared to TAU (47%; χ = 2.83, p = .046). 
Discussion: A brief psychosocial intervention with family members can decrease 
readmissions in patients with ESRD, thereby improving health outcomes and reducing 
costs. 
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